ArticleMedicine2026
Investigating a modified Yiqi Huoxue formula for chronic glomerulonephritis: Effects on clinical efficacy, renal function, and inflammation.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the clinical efficacy of a modified Yiqi Huoxue formula in patients with chronic glomerulonephritis (CGN), with a specific focus on its impact on renal function and inflammatory markers. In this Retrospective study, patients diagnosed with CGN and the information collected in the outpatient medical record between April and August 2023 were allocated to either an observation group or a control group. The control group (n = 45) received conventional basic treatment, whereas the observation group (n = 45) was administered the modified Yiqi Huoxue formula alongside conventional treatment for a duration of 8 weeks. Primary outcomes included clinical efficacy rates, while secondary outcomes encompassed measurements of renal function indices (serum creatinine [Scr], blood urea nitrogen [BUN], 24-hour urinary protein quantitation [24hUPQ]), lipid profiles (triglycerides [TG], total cholesterol, low-density lipoprotein cholesterol [LDL-C]), and inflammatory markers (interleukin-6 [IL-6], high-sensitivity C-reactive protein [hs-CRP]). A total of 90 patients were enrolled. The observation group exhibited a significantly higher clinical effectiveness rate of 86.67% compared to 66.67% in the control group (P <.05). After the 8-week intervention, posttreatment levels of Scr, BUN, and 24hUPQ were significantly lower in the observation group than in the controls (P <.05). Furthermore, significant reductions were also observed in the observation group for TG, total cholesterol, LDL-C, IL-6, and hs-CRP levels (P <.05). Multivariate logistic regression analysis identified reductions in Scr, BUN, 24hUPQ, IL-6, and hs-CRP as factors significantly correlated with clinical efficacy (P <.05). Receiver operating characteristic analysis confirmed that both renal function indicators (area under the curve = 0.848) and inflammatory markers (area under the curve = 0.739) served as reliable predictors of favorable treatment outcomes. The modified Yiqi Huoxue formula, as an adjunctive therapy, demonstrates significant clinical efficacy in the management of CGN. Its therapeutic benefits are potentially mediated through the dual mechanisms of improving renal function and attenuating systemic inflammation, thereby delaying disease progression. These findings support its clinical application for CGN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.